PerturbMind AI launches AlphaCell 1.0 Pro for omics drug discovery
PerturbMind AI has emerged from stealth, announced angel and angel+ financing totaling tens of millions of yuan, and launched the PerturbSeek digital-life world-model ecosystem. The company released AlphaCell 1.0 Pro, a geometric world model for virtual-cell state and perturbation-trajectory inference. The standard version has 1 billion parameters, with configurable versions ranging from 300 million to 50 billion parameters. PerturbMind AI says the model can support disease-mechanism analysis, target discovery and drug-response modeling. The reports state that its ability to understand complex biological systems still requires continued experimental validation and testing in actual drug-development projects.
The release combines an AI-for-science model family, the PerturbSeek platform, financing and a planned industrial path for omics-based drug research. The reports also emphasize that the model’s scientific and drug-development value still requires experimental validation and testing in real drug-development projects.
当大模型在文本、图像领域不断刷新性能上限，但把 Transformer、Pre-training、Scaling Law 直接“拿来主义”照搬到生命组学（Omics）领域，却频繁遭遇现实壁垒。组学数据高维、稀疏、动态、异质、标签稀缺，和文本、图像等 AI 适配的经典数据类型相比存在巨大鸿沟。面向组学数据，大量 AI4S 项目停留在论文原型，似乎难以真正走进实际的产业研发场景。
近期，国内 AI for Science 初创企业扰动之心（PerturbMind AI）正式走出隐匿模式，打造几何世界模型驱动的 PerturbSeek™ 数字生命世界模型生态系统，全力探索适配生命组学并有效驱动药物研发的可工程落地的 AI 技术路线。
扰动之心孵化于同济大学数字生命智能体实验室（DELTA Lab），CEO 啜国晖博士是该实验室的 90 后毕业生，首席科学家正是实验室负责人刘琦教授。团队同时发布业内首个虚拟细胞状态推演世界模型 AlphaCell 1.0 Pro，其前身是今年 3 月发布的 AlphaCell 1.0 Preview，Nature 也对其学术版本做了相关报道。
#PerturbMind AI#PerturbSeek#AlphaCell 1.0 Pro#AlphaCell 1.0 Preview#AlphaCell 1.0 Flash#AlphaCell 1.0 Mega#Tongji University DELTA Lab#Roche#AstraZeneca#WuXi AppTec